tbuckley/cabot-search huggingface dataset:
RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted?
Authors: C. Resteghini, S. Alfieri, P. Quattrone, F. Dominoni, G. Garzone, E. Orlandi, L. Locati, C. Bergamini, D. Galbiati, N.A. Iacovelli, L. Licitra, P. Bossi
Journal: Annals of Oncology (2016)
Reinforcement of Cancer Immunotherapy by Adoptive Transfer of Cblb-Deficient Cytotoxic T Lymphocytes Combined with a Dendritic Cell Vaccine
Authors: Christina Lutz-Nicoladoni, Patrizia Stoizner, Magdalena Pircher, Stephanie Wallner, Anna Maria Wolf, Guenther Gastl, Josef Penninger, Gottfried Baier, Dominik Wolf
Journal: Blood (2010)
Massive Idiopathic Oropharyngeal and Laryngeal Granulomatosis on FDG PET/CT
Authors: Yiyan Liu
Journal: Clinical Nuclear Medicine (2017)

Idiopathic granulomatosis is a rare entity and has varied manifestations and imaging findings. A 44-year-old woman with sore throat and worsening dyspnea had multiple oropharyngeal and supraglottic masses on laryngoscopic examination. FDG PET/CT demonstrated diffuse tumor-like mucosal/submucosal lesions with intense uptake involving the oropharynx, supraglottis, and hypopharynx. Surgical biopsy showed chronically inflamed granulation tissue without malignancy, necrosis, or vasculitis. All stains were negative for any organisms. The image highlights the necessity of including granulomatosis as a differential from malignancy in interpretation of FDG PET/CT showing diffuse mucosal/submucosal oropharyngeal and/or laryngeal lesions but without established diagnosis.
Productivity in the NHS grows for fifth year running, ONS data show
Authors: Matt Wilkes
Journal: BMJ (2017)

Productivity in the NHS has grown for the fifth year running, Office for National Statistics (ONS) data show.1

To calculate the figures, the ONS adjusted measures of the output of the health service for improvements in quality, and then compared total healthcare outputs in the UK from 1997 to 2014 with total healthcare inputs …
The IRON2 Study. A Retrospective Observational Study to Describe the Evolution of Iron Overload in Patients with Low-Risk Myelodysplastic Syndrome
Authors: Angel Remacha, Beatriz Arrizabalaga, Ana Villegas, Maria Soledad Duran, Lourdes Hermosin, Raquel de Paz, Marta García, Regina García, Consuelo del Cañizo, Silvia Sanz, Guillermo Sanz
Journal: Blood (2012)
Single Cell Network Profiling (SCNP) of IFN-α Signaling Pathways In Peripheral Blood Mononuclear Cells From Healthy Donors: Implications for Disease Characterization, Treatment Selection, and Drug Discovery
Authors: Diane Longo, Erik Evensen, Wendy J. Fantl, Zoltan Pos, Francesco Marincola, Alessandra Cesano
Journal: Blood (2010)
Clinical and Molecular Characterization of Fanconi Anemia: An Indian Perspective
Authors: Nancy Beryl Janet Arthur, Abhijeet P Ganapule, Dhavapriya Palani, Auro Viswabandya, Vikram Mathews, Aby Abraham, Vivi M Srivastava, Alok Srivastava, Biju George, Shaji R Velayudhan
Journal: Blood (2014)
Anaplastic astrocytoma (AA) and glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center
Authors: G. Lombardi, A. Pambuku, L. Bellu, P. Fiduccia, Alla De Puppa, M. Gardiman, F. Berti, D. D'Avella, V. Zagonel
Journal: Annals of Oncology (2016)
Proposed QOF indicators target diabetes prevention
Authors: Gareth Iacobucci
Journal: BMJ (2017)

General practices in England could be tracked on the patients they refer to the national diabetes prevention programme, under new proposals from the National Institute for Health and Care Excellence (NICE).

The proposals are outlined in a consultation that suggests 11 potential new indicators for incorporation into the Quality and Outcomes Framework or other performance monitoring schemes.1

But GPs told The BMJ that some practices could be unfairly penalised financially if the new indicators are accepted, as the national diabetes prevention programme was available to refer to in only around half of the country, with a full roll-out not expected until 2020.

The proposed new indicators include monitoring the percentage of patients with newly diagnosed non-diabetic hyperglycaemia in the preceding 12 months who have been …
Using Auto Dendritic Cells Accompanied with CIK Plus Chemotherapy As Consolidation Treatment for 59 Patients with Acute Leukemia
Authors: Zhuanzhen Zheng, Zhenhua Qiao, Wenliang Chen, Rong Gong, Yalin Wang, Lianrong Xu, Yanping Ma, Lihong Hou, Li Zhang, Yujin Lu, Bo Jiang, Guoxia Li, Chunxia Dong
Journal: Blood (2011)
EXTH-05. NANOPARTICLE-MEDIATED INHIBITION OF DNA REPAIR INCREASES SURVIVAL IN A GENETIC AFTER RADIOTHERAPY
Authors: Forrest Kievit, Kui Wang, Tatsuya Ozawa, Aria Tarudji, John Silber, Eric Holland, Richard Ellenbogen, Miqin Zhang
Journal: Neuro-Oncology (2016)

Radiotherapy is an integral component of the treatment for pediatric and adult brain tumors. However, survival is frequently accompanied by one or more radiation-induced adverse sequelae, especially in children. Therefore, strategies that enhance radiotherapy in brain tumors while sparing adjacent normal brain are expected to improve life-long outcomes. We have developed a nanoparticle delivery vehicle that can stably bind, protect, and deliver nucleic acids to brain cancer cells and tumors. We found that nanoparticle-mediated siRNA delivery reduced expression and activity of the multifunctional DNA repair protein Ape1 specifically in glioblastoma cells and tumors, which diminished their response to radiotherapy. Importantly, nanoparticle treatment (intravenous delivery) combined with 10 Gy fractionated radiotherapy doubled the extension in survival compared to 10 Gy fractionated radiotherapy alone in a PDGFB-driven genetic mouse model of glioblastoma. Therefore, nanoparticle-mediated inhibition of Ape1 may be a useful strategy to enhance the therapeutic effect of radiotherapy in brain tumor patients and reduce treatment-induced morbidity.
Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT
Authors: Courtney Lawhn-Heath, Robert R. Flavell, Christine Glastonbury, Thomas A. Hope, Spencer C. Behr
Journal: Clinical Nuclear Medicine (2017)

We present a case of an incidentally detected squamous cell carcinoma of the oropharynx on Ga-PSMA-11 PET. A 71-year-old man's condition was diagnosed as prostate carcinoma after a year of rising serum prostate-specific antigen. The staging Ga-PSMA PET/CT demonstrated focal radiotracer uptake in the prostate corresponding to his known primary prostate cancer. However, a PSMA-avid 3.4-cm mass was incidentally found in the right tongue base that was biopsied, confirming squamous cell carcinoma.
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
Authors: Nicolas L Losa, Michael Cruise, Ada Tam, Elizabeth Wick, Elizabeth Hechenbleikner, Janis M Taube, Richard Blosser, Hongni Fan, Hao Wang, Brandon Luber, Ming Zhang, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, Cynthia Sears, Robert A Anders, Drew Pardoll, Franck Housseau, Nicholas Siegel
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts We examined the immune microenvironment of primary colorectal cancer (CRC) using immunohistochemistry, laser capture microdissection/qRT-PCR, flow cytometry and functional analysis of tumor infiltrating lymphocytes. A subset of CRC displayed high infiltration with activated CD8+
TMOD-24. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF RESISTANCE TO ANTI-ANGIOGENIC THERAPY
Authors: Arman Jahangiri, William Chen, Garima Yagnik, Maxim Sidorov, Jonathan Rick, Ruby Kuang, Michael De Lay, Patrick M. Flanigan, Manish Aghi
Journal: Neuro-Oncology (2016)

Bevacizumab treatment of glioblastoma is limited by transient response and acquired resistance. To study underlying transcriptional changes, we created a novel multigenerational xenograft model of acquired resistance followed by microarray gene expression analysis. Glioblastoma cells were injected subcutaneously, treated with bevacizumab, and the fastest growing tumor reimplanted into new mice, generating paired isogeneic responsive/resistant multigenerational xenografts. Whole human genome microarray was performed on 3 tumors from generations 1, 4 and 9, with gene expression bioinformatic analysis (Matlab2014a). A two-component normal mixture model helped identify genes exhibiting significant inter-generational variance between resistant versus responsive xenografts. Extracted protein-protein interaction scores among these genes from String 10 database were used as undirected edge weights in a network representation of the significant gene set. Gene set over-representation (GSO) analysis via ConsensusPathDB identified meaningful clusters and subnetworks mediating distinct functions and molecular pathways. Gene set enrichment analysis revealed significant overexpression across generations of mesenchymal subtype gene signatures, and a tumor mesenchymal metabolic signature, peaking by generation four. Key mesenchymal markers, including putative tumor-stemness marker CD44, NT5E, SNAI2, and ZEB2, were upregulated across generations. These results suggest tumor progression under bevacizumab is accompanied by a shift in gene expression towards the mesenchymal subtype, with worse outcomes. Pro-angiogenic genes FGF2, MMP1, HIF1A, UGCG, LPAR1, and ITGB3 were upregulated. GSO analysis identified angiogenesis as a significantly enriched ontology within the inflammatory response and ECM remodeling subnetworks identified by spectral clustering. GSO identified upregulated angiogenesis-related genes including inflammatory (COX2, IL6, IL1A) and angiogenic (TGFA, WNT5A, FGF2) factors. These results suggest a mesenchymal and pro-angiogenic response to bevacizumab supported by multiple converging pathways involving inflammation, hypoxia, and ECM remodeling. Strategies preventing the evolution of these responses should be developed and tested in the context of our novel xenograft model to improve the durability of therapeutic response.
P06.10 A retrospective single-center study of IDH mutations in gliomas
Authors: M. Megova, J. Drabek, R. Trojanec, V. Koudelakova, J. Vrbkova, O. Kalita, S. Mlcochova, M. Rabcanova, L. Tuckova, M. Hajduch
Journal: Neuro-Oncology (2016)

CONCLUSION: Compared to NB, ATF5 is significantly overexpressed on mRNA level in LGA and GBM independently of tumor growth patterns.Since inhibition of ATF5 might lead to the selective death of glioma cells, but not of non-tumor cells, it might serve as a potential ubiquitous therapeutic target in astrocytic tumors, independently of WHO grading or growth pattern.
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment.
Authors: Marco Ladetto, Federica De Marco, Fabio Benedetti, Umberto Vitolo, Caterina Patti, Alessandro Rambaldi, Alessandro Pulsoni, Maurizio Musso, Anna M. Liberati, Attilio Olivieri, Andrea Gallamini, Enrico Pogliani, Delia Rota Scalabrini, Vincenzo Callea, Francesco Di Raimondo, Vincenzo Pavone, Alessandra Tucci, Sergio Cortelazzo, Alessandro Levis, Mario Boccadoro, Ignazio Majolino, Alessandro Pileri, Alessandro M. Gianni, Roberto Passera, Paolo Corradini, Corrado Tarella
Journal: Blood (2007)
The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna
Authors: B. Kiesewetter, M. Raderer, C. Marosi, T. Brodowicz, G. Prager, M. Krainer, T. Fuereder, G.J. Locker, C.C. Zielinski
Journal: Annals of Oncology (2016)
Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center.
Authors: Jane L. Liesveld, Camille N. Abboud, Stephen H. Bernstein, Jonathan Friedberg, Jainulabdeen J. Ifthikharuddin, Louis S. Constine, Karen L. Kaplan, Lucy A. Wedow N.P., Diane D. Nichols, Jamie Oliva, Maryanne Etter, Gordon L. Phillips
Journal: Blood (2005)
Latent Iron Metabolism Disturbances in Fertile Women and Its Detection with the Automated Hematology Instrument LH750®.
Authors: Maria J. Capel-Casbas, Jose J. Duran, Jorge Diaz, Gerardo Ruiz, Ramon Simon, Francisco Rodriguez, Josep Piqueras, Dolors Pelegri, Nuria Pujol-Moix
Journal: Blood (2005)
Pharmacogenetics of Response to Glucocorticosteroids in Adults with Acute Lymphoblastic Leukemia.
Authors: Krzysztof Jamroziak, Ewa Balcerczak, Zofia Szemraj, Aleksandra Salagacka, Olga Grzybowska-Izydorczyk, Barbara Cebula, Janusz Szemraj, Marek Mirowski, Tadeusz Robak
Journal: Blood (2006)
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
Authors: K. Tamura, K. Shitara, Y. Naito, A. Shimomura, Y. Fujiwara, K. Yonemori, C. Shimizu, T. Shimoi, Y. Kuboki, N. Matsubara, A. Kitano, T. Jikoh, Y. Fujisaki, A. Yver, T. Doi
Journal: Annals of Oncology (2016)
KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
Authors: S. Lonial, M. Ribeiro de Oliveira, H. Yimer, M.V. Mateos, R. Rifkin, F. Schjesvold, J. San-Miguel, R. Ghori, P. Marinello, S. Jagannath
Journal: Annals of Oncology (2016)
Tepotinib plus gefitinib in patients with c-Met-positive/EGFR-mutant NSCLC: Recommended phase II dose (RP2D), tolerability, and efficacy
Authors: Y.-L. Wu, R. Soo, D.-W. Kim, J. Yang, U. Stammberger, W. Chen, G. Locatelli, K. Park
Journal: Annals of Oncology (2016)
SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies
Authors: Maureen C. Ryan, Brian Schimpf, Martha Anderson, Weiping Zeng, Kim Emmerton, Jamie Miyamoto, Heather Kostner, Changpu Yu, Heather Van Epps, Laurie Tatalick, Dennis Benjamin
Journal: Blood (2015)
Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).
Authors: Donna E. Reece, Giovanni Piza Rodriguez, Andrew Belch, David Szwajcer, Mariela Pantoja, Michael Kovacs, Chaim Shustik, Nizar J Bahlis, Darrell J White, Christine Chen, Vishal Kukreti, Peter Anglin, A. Keith Stewart, Suzanne Trudel
Journal: Blood (2009)
Capillary Hemangioma of Thoracic Spinal Cord
Authors: Guohua Shen, Minggang Su, Junyi Zhao, Bin Liu, Anren Kuang
Journal: Clinical Nuclear Medicine (2017)

Capillary hemangiomas are frequently encountered superficially in the cutaneous, subcutaneous, or mucosal tissues during the childhood and early adulthood, but the occurrence of spinal intradural capillary hemangioma is relatively rare. Herein, we report a case with capillary hemangioma of the thoracic spine. MR and PET/CT features of this lesion are presented, and awareness of this entity may help differentiate it from other spinal intradural tumors.
Single Large Dose (15 Mg/Kg) Amphotericin B Lipid Complex (L-AmB) as Prophylaxis of Fungal Infections during Induction Chemotherapy in Acute Non Lymphoid Leukemia (ANLL).
Authors: Anna Chierichini, Susanna Fenu, Marina Persiani, Stefania Cortese, Maria Iris Cassetta, Andrea Novelli, Luciana Annino
Journal: Blood (2005)
CSIG-14. SPROUTY2 DIFFERENTIALLY REGULATES SIGNALING AND PHENOTYPIC RESPONSES OF GLIOBLASTOMA CELLS TO DNA DAMAGING AGENTS AND RECEPTOR KINASE INHIBITORS
Authors: Nisha Sosale, Matthew Lazzara
Journal: Neuro-Oncology (2016)

Key to improving glioblastoma patient survival is exploration of the signaling mechanisms that regulate cellular response to approved and investigational therapeutics, including DNA damaging agents and targeted therapeutics such as EGFR and MET kinase inhibitors. Previous work from our group demonstrated that Sprouty2 (SPRY2) surprisingly acted more as a tumor promoter than tumor suppressor in glioblastoma cell lines and tumor xenografts, with SPRY2 knockdown reducing proliferation of human glioblastoma cells and antagonizing the growth of subcutaneous tumor xenografts in mice. Here, we explored the role of SPRY2 in modulating the response of glioblastoma cells to different classes of cancer therapeutics: DNA damaging agents and targeted inhibitors of oncogenic kinases. We found that SPRY2 knockdown potentiated glioma cell line response to both classes of therapeutics. In other words, the normal expression of SPRY2 in glioblastoma cells interferes with cell-autonomous responses that would otherwise lead to greater amounts of cancer cell death, pointing to SPRY2 as a broad driver of glioblastoma resistance to therapy. We went on to survey dynamic alterations in signaling pathways for DNA damage response, proliferation, and survival. We then modeled the relationship between the cell death data and the signaling measurements using partial least squares regression, a data-driven computational modeling approach. Our analysis revealed that a core subset of kinase-driven signaling processes, spanning multiple distinct signaling pathways that are common to cellular response to both classes of therapeutics, is responsible for explaining how SPRY2 broadly modulates glioma response to therapeutics.
Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331
Authors: Leonard A. Mattano, Meenakshi Devidas, Alison M. Friedmann, Elizabeth A. Raetz, Mignon Loh, Patrick Buckley, Michael J. Borowitz, Andrew J. Carroll, Julie Gastier-Foster, Nyla A. Heerema, Nina Kadan-Lottick, Yousif Matloub, David T Marshall, Linda C. Stork, Brent L. Wood, Naomi J. Winick, Stephen Hunger, William L. Carroll, Kelly Maloney
Journal: Blood (2014)
HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation
Authors: Xiaoyu Jiang, Isabel Romero-Camarero, Xiaoqing Lu, Carolina Vicente-Dueñas, Ines Gonzalez-Herrero, Teresa Flores, Juan Luis Garcia, George McNamara, Christian Kunder, Yasodha Natkunam, Victor Segura, Lorenna Fontan-Gabas, Jose A Martinez-Climent, Ash A Alizadeh, Cesar Cobaleda, Isidro Sanchez-Garcia, Izidore S Lossos
Journal: Blood (2011)
STMC-29. GENETIC ENGINEERING OF GLIOMA CELLS WITH HISTONE-2B-GFP TAG TO TRACK AND CHARACTERIZE QUIESCENT GLIOMA STEM CELLS
Authors: Rut Tejero, Yong Huang, Jessica Tome-Garcia, Hongyan Zou, Roland Friedel
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most common malignant brain tumor with a dismal prognosis and limited therapy options. Advances in culture methods have led to the establishment of patient-derived glioma stem cell (GSC) lines that preserve genomic and physiologic characteristics of GBM. Quiescent populations of GSCs have been proposed as the main source of GBM recurrence after therapy. We are applying CRISPR to introduce a doxycycline inducible histone-2B-GFP (H2B-GFP) labeling system at the AAVS1 locus, a “safe harbor” for transgene insertions. The H2B-GFP label allows to track and isolate quiescent glioma cells that retain high GFP label (dividing cells dilute H2B-GFP), and to characterize their cancer stem cell properties. We have transfected GSC lines with an AAVS1 Cas9 plasmid and a targeting plasmid carrying Tet-ON transactivator M2rtTA and tetO-H2B-GFP. Cells with integrated targeting vector were selected with G418, and insertions were confirmed by PCR over 5’ and 3’ arms. H2B-GFP GSC lines were transplanted intracranially into the striatum of SCID mice, and after an initial pulse period of 2 weeks (doxycycline-ON), tumors are allowed to expand during chase periods of 2, 4, or 8 weeks. Subcohorts of mice are subjected to radiation therapy to elucidate the contribution of quiescent GSC to radiation resistance. We are using histology to reveal the quiescent cell populations (GFP-high) in tumors, their spatial distribution and proximity to vascular niches, and their molecular features. GFP-high (quiescent) and GFP-low (proliferating) populations of tumor cells are separated by FACS, and populations are assessed by in vitro assays to elucidate whether the proliferative history of GSCs leaves a lasting imprint on future proliferation, differentiation, or migration behaviors. Finally, we are also using FACS sorted populations to isolate RNA and generate expression profiles by RNA-Seq, which will allow us to identify new molecular markers of quiescent glioma stem cells.
TMOD-08. PDX MODELING OF RECURRENT GLIOBLASTOMA FOR TESTING SALVAGE THERAPIES
Authors: C. David James, Atique Ahmed, Jeffrey Raizer, Maciej Lesniak, Craig Horbinski, Priya Kumthekar
Journal: Neuro-Oncology (2016)

Nearly all rodent model testing of candidate therapies for glioblastoma (GBM) rely on the use of previously untreated tumor cell sources for tumor establishment in rodents. However, most novel therapeutics are initially tested in clinical trials for treating GBM that have been exposed to, and recurred following radiation therapy (RT) and temozolomide (TMZ) chemotherapy. Therefore, there is a need for in vivo modeling of recurrent GBM, in order to obtain preclinical results that are more likely to predict candidate therapeutic anti-tumor activity against GBM in patients with recurrent tumor. In this study we have used a previously untreated patient derived xenograft (PDX), established from a GBM, for engrafting intracranial tumors in athymic mice that began receiving RT (2 Gy/day x 5) + TMZ (10 mg/kg x 5) on day 6 post-tumor cell implantation. Control untreated mice succumbed to growing tumor between days 22 and 26 post-tumor cell implantation. Sequential tumor bioluminescence readings revealed tumor regression in mice receiving RT + TMZ therapy. However, RT + TMZ treated tumors recurred between days 37 and 56 post-implantation. At time of tumor recurrence, mice either received no further treatment, or were given 30 mg/kg CCNU 1x/week. Thus far, 6 of 7 mice receiving no further treatment have succumbed to recurrent tumor (days 55-69 post-implantation), whereas all mice receiving CCNU treatment (n=9) remain alive at day 69 post-implantation (p < 0.001). Results from flow cytometry and immunohistochemical analysis of untreated, RT + TMZ treated, and RT + TMZ + CCNU treated tumors will be presented at the meeting. Current results indicate that we have developed an approach for in vivo modeling recurrent GBM. We anticipate that this method will prove generalizable for different GBM cell sources, and that PDX models of recurrent GBM will be useful in identifying effective salvage therapies.
Research of Synergetic Reversal in Adriamycin - Resistance by the Application of Magnetic Nanoparticle of Fe3O4 and Tetrandrine in K562/A02 Leukemic Cells.
Authors: Bao-An Chen, Qian Shun, Xue-Mei Wang, Ren-Yu Zhang, Feng Gao, Jian Chen, Chong Gao, Jun Wang, Jia-Hua Ding, Gang Zhao, Ning-Na Chen, Xiao-Ping Pei, Yong-Yuan Dai, Ning Shun
Journal: Blood (2007)
Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20
Authors: T. Aparicio, O. Bouché, E. Francois, E. Maillard, S. Kirscher, J. Taieb, P.-L. Etienne, R. Faroux, F. Khemissa Akouz, F. El Hajbi, C. Locher, Y. Rinaldi, T. Lecomte, S. Lavau-Denes, M. Baconnier, A. Oden-Gangloff, D. Genet, E. Paillaud, F. Retornaz, L. Bedenne
Journal: Annals of Oncology (2016)
Nodding syndrome may be an autoimmune reaction to the parasitic worm <i>Onchocerca volvulus</i>
Authors: Tory P. Johnson, Richa Tyagi, Paul R. Lee, Myoung-Hwa Lee, Kory R. Johnson, Jeffrey Kowalak, Abdel Elkahloun, Marie Medynets, Alina Hategan, Joseph Kubofcik, James Sejvar, Jeffrey Ratto, Sudhir Bunga, Issa Makumbi, Jane R. Aceng, Thomas B. Nutman, Scott F. Dowell, Avindra Nath
Journal: Science Translational Medicine (2017)

Patients with nodding syndrome have autoantibodies to leiomodin-1 that are neurotoxic and cross-react with proteins of the parasitic worm Onchocerca volvulus .